Therapeutic Advancements in Psoriasis and Psoriatic Arthritis DOI Open Access

Robin C. Yi,

Maya Akbik, Logan R. Smith

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(4), P. 1312 - 1312

Published: Feb. 16, 2025

Background: Within the past few years, many new therapies have emerged for psoriasis and psoriatic arthritis (PsA). Current topical therapies-including corticosteroids, vitamin D analogs, tapinarof, roflumilast-remain mainstay mild disease, while oral systemic biologic options are moderate to severe cases. Biologics-such as Tumor necrosis factor-alpha (TNF-alpha), Interleukin 12/23 (IL-12/23), Interleukin-17 (IL-17), Interleukin-23 (IL-23)-have revolutionized care by providing highly effective safer alternatives. Oral small molecules, including Janus kinase (JAK) tyrosine 2 (TYK2) inhibitors, further expand therapeutic options. Objectives: The goal this review article was examine current latest treatments PsA discuss whether these emerging address unmet needs of treatments. Methods: search included PubMed, Google Scholar, ClinicalTrials.gov relevant articles clinical trials using keywords. Results: A wide range novel currently undergoing trials. These include selective JAK TYK2 retinoic acid-related orphan receptor (RORγT) IL-23 IL-17A nanobody products, sphingosine-1-phosphate (S1P1R) antagonists, A3 adenosine (A3AR) agonists, heat shock protein (HSP) 90 rho-associated kinases (ROCK-2) inhibitors. Conclusions: different mechanisms action not only treatment but may offer potential solutions patients who do achieve adequate response with existing therapies. However, safety contraindications newer agents remain an important consideration ensure appropriate patient selection minimize risks. Certain pose increased risks infection, cardiovascular manifestations, malignancy, or other immune-related adverse events, necessitating careful monitoring individualized decisions. Ongoing research aims respond previous sustained remission, monitor long-term outcomes, assess preferences delivery, a preference delivery. inhibitors hold due their robust profiles. In contrast, IL-17 TYK-2 present side effects that could impact acceptability. It is essential balance efficacy, safety, guide

Language: Английский

Therapeutic Advancements in Psoriasis and Psoriatic Arthritis DOI Open Access

Robin C. Yi,

Maya Akbik, Logan R. Smith

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(4), P. 1312 - 1312

Published: Feb. 16, 2025

Background: Within the past few years, many new therapies have emerged for psoriasis and psoriatic arthritis (PsA). Current topical therapies-including corticosteroids, vitamin D analogs, tapinarof, roflumilast-remain mainstay mild disease, while oral systemic biologic options are moderate to severe cases. Biologics-such as Tumor necrosis factor-alpha (TNF-alpha), Interleukin 12/23 (IL-12/23), Interleukin-17 (IL-17), Interleukin-23 (IL-23)-have revolutionized care by providing highly effective safer alternatives. Oral small molecules, including Janus kinase (JAK) tyrosine 2 (TYK2) inhibitors, further expand therapeutic options. Objectives: The goal this review article was examine current latest treatments PsA discuss whether these emerging address unmet needs of treatments. Methods: search included PubMed, Google Scholar, ClinicalTrials.gov relevant articles clinical trials using keywords. Results: A wide range novel currently undergoing trials. These include selective JAK TYK2 retinoic acid-related orphan receptor (RORγT) IL-23 IL-17A nanobody products, sphingosine-1-phosphate (S1P1R) antagonists, A3 adenosine (A3AR) agonists, heat shock protein (HSP) 90 rho-associated kinases (ROCK-2) inhibitors. Conclusions: different mechanisms action not only treatment but may offer potential solutions patients who do achieve adequate response with existing therapies. However, safety contraindications newer agents remain an important consideration ensure appropriate patient selection minimize risks. Certain pose increased risks infection, cardiovascular manifestations, malignancy, or other immune-related adverse events, necessitating careful monitoring individualized decisions. Ongoing research aims respond previous sustained remission, monitor long-term outcomes, assess preferences delivery, a preference delivery. inhibitors hold due their robust profiles. In contrast, IL-17 TYK-2 present side effects that could impact acceptability. It is essential balance efficacy, safety, guide

Language: Английский

Citations

0